Literature DB >> 8270973

Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.

R Rossi1, A Gödde, A Kleinebrand, M Riepenhausen, J Boos, J Ritter, H Jürgens.   

Abstract

PURPOSE: This study was performed to identify risk factors of ifosfamide-induced renal damage. PATIENTS AND METHODS: Renal function was assessed in 120 patients at a minimum of 3 months after completion of chemotherapy including ifosfamide. The cumulative ifosfamide dose ranged from 2 to 95 g/m2 (median, 30 g/m2). Ten patients had undergone unilateral nephrectomy; combination cytostatic treatment included cisplatin in 51 and methotrexate in 57. Sixty-eight patients had received gentamicin treatment. The glomerular filtration rate was estimated using the Schwartz formula. Proximal tubular function was assessed by the percent reabsorptions of glucose and 16 amino acids, the fractional excretion of sodium, and the fractional reabsorption of phosphate. In addition, the serum bicarbonate level was measured.
RESULTS: Proximal tubular dysfunction--with a predominance of renal amino acid (66.3%) and phosphate loss (38.3%)--was much more frequent than both glomerular impairment and acidosis. Seven patients were identified as having renal Fanconi's syndrome, and generalized tubulopathy was noted in another 15 patients. Ifosfamide-induced nephrotoxicity was dose-dependent, with a weak linear inverse correlation between cumulative ifosfamide dose and fractional phosphate reabsorption. Unilateral nephrectomy proved to be the single most important risk factor (odds ratio for the development of renal Fanconi's syndrome, 11.4), but cisplatin also significantly enhanced ifosfamide-mediated nephrotoxicity. Methotrexate, gentamicin, and patient age at primary diagnosis had no influence on renal function.
CONCLUSION: Ifosfamide chemotherapy should probably be restricted in patients after unilateral nephrectomy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8270973     DOI: 10.1200/JCO.1994.12.1.159

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  30 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Genitourinary long-term outcomes for childhood cancer survivors.

Authors:  Margarett Shnorhavorian; Debra L Friedman; Martin A Koyle
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

4.  Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid.

Authors:  Tomokazu Matsuura; Shu Wakino; Ayumi Yoshifuji; Toshifumi Nakamura; Hirobumi Tokuyama; Akinori Hashiguchi; Konosuke Konishi; Takeshi Iwasa; Masaaki Shoji; Ako Hosono; Ken Ohashi; Hirokazu Chuman; Hiroshi Itoh
Journal:  CEN Case Rep       Date:  2014-06-04

Review 5.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

6.  6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.

Authors:  E C Brain; A Mita; P Soulié; H Errihani; A C Hardy Bessard; M Chaouche; J Alexandre; J P Delord; E Cvitkovic; C Jasmin; J L Misset
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 7.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

8.  Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

Authors:  Darren R Feldman; Ilya Glezerman; Sujata Patil; Lindsay Van Alstine; Dean F Bajorin; Patricia Fischer; Amanad Hughes; Joel Sheinfeld; Manjit Bains; Lilian Reich; Kaitlin Woo; Sergio Giralt; George J Bosl; Robert J Motzer
Journal:  Clin Genitourin Cancer       Date:  2015-05-16       Impact factor: 2.872

9.  Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.

Authors:  Hiroaki Nishimura; Hideki Enokida; Satoshi Nagano; Masahiro Yokouchi; Hiroshi Hayami; Setsuro Komiya; Masayuki Nakagawa
Journal:  J Artif Organs       Date:  2013-10-04       Impact factor: 1.731

10.  Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.

Authors:  Najat C Daw; David Gregornik; John Rodman; Neyssa Marina; Jianrong Wu; Larry E Kun; Jesse J Jenkins; Valerie McPherson; Judith Wilimas; Deborah P Jones
Journal:  Eur J Cancer       Date:  2008-11-06       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.